Prnewswire·2025-09-25 11:42Core Insights - WuXi Biologics has launched TrueSite TI™, a targeted integration-based CHO cell line platform aimed at enhancing biologics development by improving timelines, product quality, and scalability for antibody and complex protein therapies [1][4]. Technology Overview - Targeted integration is a precise cellular engineering technique that allows for the delivery of expression units to specific locations in host cells, streamlining development and reducing the number of clones needed for screening [2]. - TrueSite TI™ is the fourth generation of the WuXia™ cell line platform, which has been validated in over 1000 molecules over the past decade, achieving an average monoclonal antibody (mAb) titer exceeding 8.0 g/L and maintaining over 99% of clonal cell lines' stability after 60 generations [3][5]. Development Efficiency - The platform enables a 6-month IND timeline, significantly accelerating the development of innovative therapies and their path to commercial launch [6][7]. - TrueSite TI™ is particularly effective for mAb development and has shown strong applicability for complex biologics, including bispecific antibodies, Fc-fusion proteins, and Fab fragments, ensuring consistent quality and stability [3][6]. Company Vision - The CEO of WuXi Biologics emphasized the importance of cell line development in delivering high-quality therapies faster, highlighting the advancements made with the TrueSite TI™ platform in both quality and efficiency [4].